OncoMatch/Clinical Trials/NCT05294055
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Is NCT05294055 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Etoposide and Cyclophosphamide for multiple myeloma.
Treatment: Etoposide · Cyclophosphamide · Mecapegfilgrastim, day 2 · Mecapegfilgrastim, day 5 — This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received:
Patients who had achieved at least partial response (PR)
Cannot have received: hematopoietic stem cell mobilization
Patients who had previously attempted hematopoietic stem cell mobilization
Cannot have received: bone marrow transplantation
Patients who had undergone previous bone marrow transplantation
Cannot have received: lenalidomide (lenalidomide)
Exception: more than 4 cycles or received within 4 weeks prior to mobilization chemotherapy
Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy
Cannot have received: fludarabine (fludarabine)
Patients who previously been treated with fludarabine
Cannot have received: melphalan (melphalan)
Patients who previously been treated with melphalan
Cannot have received: radiation therapy
Exception: plan to receive radiation within 30 days after transplantation or had received radiation therapy in the pelvis
Patients who plan to receive radiation within 30 days after transplantation; Patients who had received radiation therapy in the pelvis
Lab requirements
Blood counts
White blood cell count (WBC) <2.5×10^9/L; Absolute neutrophil count (ANC) <1.5×10^9/L; Platelets count (PLT) <80×10^9/L [excluded]
Kidney function
Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min [excluded]
Liver function
AST/ALT/Total bilirubin > 2.5 X ULN [excluded]
Cardiac function
angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval >500ms, left ventricular ejection fraction (EF)<60%, or other heart diseases that the investigator considers unsuitable
Patients with angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval >500ms, left ventricular ejection fraction (EF)<60%, or other heart diseases that the investigator considers unsuitable for hematopoietic stem cell mobilization or hematopoietic stem cell transplantation; White blood cell count(WBC)<2.5×10^9/L; Absolute neutrophil count(ANC)<1.5×10^9/L; Platelets count(PLT)<80×10^9/L; Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min; AST/ALT/Total bilirubin > 2.5 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify